CYTK
Cytokinetics·NASDAQ
--
--(--)
--
--(--)
5.95 / 10
Netural
Analyst consensus is 75% Buy, 25% Neutral across four firms, with a weighted rating of 4.05/10. Money‑flow is good (7.85), showing overall inflow but block and extra‑large investors are net out, suggesting mixed liquidity.
Fund Flow Rating
Analyst RatingBuy
Wall Street Opinions
Buy
Strong Buy
0%
Buy
75%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-03-06
InstitutionUBS
Times predicted2
Historical Win Rate0.0%
Is money flowing into or out of CYTK?
- CYTK holds a Bearish analyst rating, with 75% of experts assigning a Buy grade. Factoring in net Inflows from order flow data, the comprehensive Sentiment Score stands at 5.95/10 (Netural).
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
